HIV

Taking stock of existing barriers to sexual and reproductive health of girls and women in SSA and how collaboration and innovation can help shape the future

Retrieved on: 
수요일, 4월 10, 2024
Tiko, CAPE, Government, Learning, UNFPA, Non-governmental organization, Agility, HIV, United, Ageing, United Nations, Shattered Dreams, Economic development, Development impact bond, Private sector, Death, Pregnancy, Adolescence, STI, Woman, Social stigma, Senior counsel, NEWS, Feedback, Health, HIV/AIDS, Tech, Birth control

For years, women and girls have been failed by a fragmented, under-resourced health system that is not built to meet their sexual and reproductive health needs.

Key Points: 
  • For years, women and girls have been failed by a fragmented, under-resourced health system that is not built to meet their sexual and reproductive health needs.
  • Coupled with HIV, complications during pregnancy and childbirth are the leading cause of death for young women aged 15-19 years.
  • "Tiko" which provides access to free reproductive health services that can change the course of many lives offering youth-friendly care and comprehensive information.
  • Achieving universal access to sexual and reproductive health and rights by 2030 will require close collaboration by stakeholders in developing innovative solutions that can dismantle barriers to access among women and girls.

The Canadian Centre on Substance Use and Addiction Welcomes Scott Elliott to its Board of Directors

Retrieved on: 
월요일, 4월 8, 2024
Addiction, Mental health, Chair, Substance, HIV, Knowledge, The Honourable, Research, Health Canada, Parliament, DSM-IV codes, CCSA

“Scott is known for his efforts in tackling substance use health issues and finding unique, powerful solutions.

Key Points: 
  • “Scott is known for his efforts in tackling substance use health issues and finding unique, powerful solutions.
  • Mr. Elliott is the Chief Executive Officer of the Dr. Peter Centre in Vancouver, B.C.
  • The Centre provides clinical, social and psychological support to marginalized community members living with HIV, complex medical conditions, mental illness, and substance use and addictions.
  • “People in Canada will benefit from Scott’s understanding of community building and the diverse experiences across substance use health.”
    Mr. Elliott joins 12 other directors to complete CCSA’s volunteer Board of Directors.

Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

Retrieved on: 
월요일, 4월 8, 2024
AP, Infection, HIV, Nature Biotechnology, Epitope, Cancer, SARS-CoV-2, Gritstone bio, HLA, AACR, Immunity, EDGE, Poster, Vaccine

EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today presented an update on its T cell epitope discovery platform, EDGE, at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 (Nature Biotechnology). It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.

Key Points: 
  • The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 ( Nature Biotechnology ).
  • It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.
  • “Identifying which of the hundreds of tumor mutations are most likely to serve as neoantigens, key targets of tumor-specific T cells, is critical to the development of effective neoantigen-directed vaccines,” said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio.
  • The improvements we are making to EDGE, leveraging advances in protein large language models and in-house immunopeptidomics, have positioned EDGE as a leading HLA/peptide predictive platform in the neoantigen cancer vaccine field.

Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates

Retrieved on: 
목요일, 4월 4, 2024
CGM, Consultant, Negotiation, Conference, Growth, Data analysis, HIV, Himawari (satellites), Diabetes, World Health Organization, Acquisition, American depositary receipt, Diagnosis of HIV/AIDS, Units of paper quantity, Clinical trial, Injection, Balance sheet, Waveform, Pharmaceutical industry

DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.

Key Points: 
  • DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.
  • We expect to have fully executed this change by the end of 2024 and expect this will deliver significant annualised savings.
  • The assets and liabilities attributable to Fitzgerald Industries have been removed from our Consolidated Balance Sheet as of December 31, 2023.
  • Total revenues for Q4, 2023 were $13.4m which compares to $15.7m in Q4, 2022, a decrease of 14.6% and which were broken down as follows:

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on: 
목요일, 4월 4, 2024
Escherichia coli, Central Bureau, Statistics, Burn, PCT, Shingles, Biotechnology, Growth, Disease, HIV, Klebsiella pneumoniae, COVID-19, Inhalation, HCMV, ASX, RCE, Recce, Viral, Pseudomonas aeruginosa, Virus, EBV, SARS-CoV-2, Staphylococcus aureus, Gonorrhea, Cytomegalovirus, Ross River virus, Neisseria meningitidis, GDP, Urinary tract infection, Skin, Streptococcus pyogenes, Patent, Staphylococcus, Streptococcus pneumoniae, Simplex, Infection, USD, Administration, Biology, Ageing, Pharmaceutical industry

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
  • “We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Tilray Medical Announces New Scientific Publication on Age-Related Patterns of Medical Cannabis Use

Retrieved on: 
수요일, 4월 3, 2024
Epilepsy, CCPS, Health, TLRY, HIV, Arthritis, Post-traumatic stress disorder, Patient, Tilray, Anxiety, Tobacco, Chronic pain, CBD, Essential tremor, Cannabis, TSX, Signs and symptoms, Pain, THC, Vomiting, Pharmaceutical industry

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, today announced a new Tilray led scientific publication, Age-related Patterns of medical Cannabis Use: A Survey of Authorized Patients in Canada. The new study was derived from the Canadian Cannabis Patient Survey (CCPS) 2021, comprised of 2,697 patients and focused primarily on older patients with a mean age of 54.3. This study presents to the medical and scientific community the consumption trends observed in patients and the self-reported impacts from medical cannabis in alleviating the patients’ primary symptoms.

Key Points: 
  • Tilray Led Study Shows Chronic Pain, Arthritis, Anxiety, and Insomnia as Primary Illnesses and Symptoms for Medical Cannabis Use
    NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, today announced a new Tilray led scientific publication, Age-related Patterns of medical Cannabis Use: A Survey of Authorized Patients in Canada .
  • This study presents to the medical and scientific community the consumption trends observed in patients and the self-reported impacts from medical cannabis in alleviating the patients’ primary symptoms.
  • The Age-related Patterns of Medical Cannabis Use study finds that older patients comprise a growing subset of medical cannabis patients.
  • José Tempero, Tilray’s Medical Director, said, "Our role in this initiative exemplifies our commitment to medical research, leading us one step closer to unlocking the full therapeutic potential of medical cannabis."

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Retrieved on: 
수요일, 4월 3, 2024
Ventricular septal defect, DCN, Disease, HIV, Patient, CTD, Connective tissue disease, Death, Parkinson's disease, Imatinib, IND, Pulmonary hypertension, Woman, Therapy, Heart, Safety, Division, WHO, HIV/AIDS, Stomach, PAH, FDA, Blood, Food, Pharmaceutical industry

The meeting will be held on April 5, 2024, with meeting results to be reported following receipt of the formal meeting minutes.

Key Points: 
  • The meeting will be held on April 5, 2024, with meeting results to be reported following receipt of the formal meeting minutes.
  • “Following our pre-NDA discussion with the FDA related to the path to approval for IkT-001Pro in up to 11 blood and stomach cancers in January, we requested an additional FDA meeting with the Division of Cardiology and Nephrology to discuss Pro as a treatment for Pulmonary Arterial Hypertension,” said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase.
  • “PAH is a rare condition that primarily afflicts women between the ages of 30 and 60 and can lead to premature heart failure and death.
  • We believe that Pro may be a be a safer and better tolerated therapeutic option for imatinib treatment in PAH.

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Retrieved on: 
화요일, 3월 26, 2024
Connected, HIV-1, Amazon Prime Video, Breast milk, Face, Hypoesthesia, Patient, Chronic pain, Clostridioides, Heartburn, Lymph, Magnesium, Diarrhea, Myalgia, Spine, Allergy, Muscle weakness, Vonoprazan, Stomach, Vitamin, Dizziness, Potassium, Hip, Risk, Tongue, Chills, DTC, Safety, Food, PPI, Rash, Food and Drug Administration, GERD, Enzyme inhibitor, Skin, Esophagitis, HIV, Rilpivirine, Kidney, FDA, Esophagus, B-12, Weakness, Infection, Indigestion, Smart TV, Seizure, Inflammation, Polyp, Calcium, Extrapyramidal system, Bone fracture, Nausea, Spasm, Urine, Fever, Clostridioides difficile, Bleeding, Blood, Wrist, Blister, Vitamin B12, Human, Medicine, Pharmaceutical industry

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

Key Points: 
  • The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
  • “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
  • To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
  • Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

Stephanie Carman Joins Underscore Marketing as SVP Client Services; Tiffany Marg Joins Strategy Team

Retrieved on: 
화요일, 4월 9, 2024
Data Analytics, General Health, Health, Marketing, Advertising, Communications, Professional Services, Business, Cooking, Growth, Learning, EVP, Disease, Marg, HIV, Steph, Diabetes, Nursing, SVP, KOL, BMS, Evoke, Overalls, Senior, Dog, Creativity, LTC, Multimedia, Tiff, EMT, Management

View the full release here: https://www.businesswire.com/news/home/20240408262170/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240408262170/en/
    Tiffany Marg & Steph Carman (Photo: Business Wire)
    Tiffany has over 20 years of experience in pharmaceutical marketing, building brands and executing campaigns.
  • In her previous role as SVP of Client Services, Tiffany was dedicated to building a first-class service team for Underscore’s clients, ensuring alignment between their ongoing business needs and goals and the execution of Underscore’s strategy and solutions.
  • Tiffany stated, “I am proud of the team we’ve built to lead our client engagements at Underscore and am excited for this next opportunity.
  • I originally came to Underscore because I was passionate about ensuring alignment between clients’ business objectives, brand and creative strategy, and media engagement strategy.

ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV

Retrieved on: 
월요일, 4월 8, 2024
Research, Infectious Diseases, FDA, LGBTQ+, AIDS, Pharmaceutical, Consumer, Health, Science, Other Science, ARV, Week, DANCE, ViiV Healthcare, Pfizer, TANGO, HIV, GSK, Ageing, Safety, Subtypes of HIV, Shionogi, Food, Pharmaceutical industry

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the U.S. Food and Drug Administration (FDA) approved Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection in adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato.1

Key Points: 
  • ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the U.S. Food and Drug Administration (FDA) approved Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection in adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato.1
    In the U.S., 20 percent of new HIV diagnoses in 2020 were among young people aged 13-24.2 This expanded indication marks the first time an oral, two-drug, single-tablet regimen is available for adolescents between 12- and 18-years old living with HIV and underscores ViiV Healthcare’s ongoing commitment to bringing more therapeutic options to young people.
  • Lynn Baxter, Head of North America at ViiV Healthcare, said: "This expanded indication for Dovato brings an oral, two-drug, single-tablet regimen to adolescents living with HIV, providing a complete HIV therapy with fewer ARV medicines – an important consideration for young people who will require lifelong treatment.
  • As a leader in HIV, ViiV Healthcare is proud of our focused efforts to improve and expand care for children and adolescents and we remain committed to addressing the existing treatment gaps in these communities.”
    The approval is supported by data from the DANCE study which evaluated Dovato in treatment-naïve adolescents as well as evidence from well-controlled trials in adults living with HIV, GEMINI-1 and GEMINI-2 (treatment-naïve adults) and TANGO (treatment-experienced adults).1 Results from the DANCE study, which included adolescents between 12- and 18-years old weighing at least 25 kg with HIV-1 RNA 1000 to ≤500,000 c/mL, showed that 26/30 participants achieved and maintained viral suppression at Week 48.1 The safety and efficacy data in adolescents from the DANCE study were comparable to those observed in adults.1 Exposures for components of Dovato were higher but were not clinically significant.1